LESSONS LEARNED
• The findings of this prospective, single-arm, phase II study showed that neoadjuvant erlotinib was well tolerated and might improve the radical resection rate in patients with stage IIIA-N2 epidermal growth factor receptor mutationpositive non-small cell lung cancer (NSCLC).
• Erlotinib shows promise as a neoadjuvant therapy option in this patient population.
• Next-generation sequencing may be useful for predicting outcomes with preoperative tyrosine kinase inhibitors (TKIs) in patients with NSCLC.
• Large-scale randomized controlled trials investigating the role of TKIs in perioperative therapy, combining neoadjuvant and adjuvant treatments to enhance personalized therapy for patients in this precision medicine era, are warranted.
DISCUSSION
Patients with stage IIIA-N2 NSCLC have a poor prognosis, especially those with EGFR mutations. Sufficient clinical benefit cannot be achieved with chemoradiotherapy without serious safety concerns. EGFR TKI therapy has shown good efficacy and favorable tolerability in patients with EGFR mutation-positive NSCLC. The TKI erlotinib is approved for first-line treatment of EGFR mutation-positive NSCLC; however, its usefulness as neoadjuvant therapy in patients with resectable EGFR mutation-positive NSCLC remains unclear.
We performed a single-arm trial to evaluate whether neoadjuvant erlotinib improves operability and survival in patients with stage IIIA-N2 EGFR mutation-positive NSCLC. The primary endpoint was the radical resection rate, and the estimated sample size was 30 cases. Of 44 patients diagnosed with stage IIIA-N2 NSCLC, 25 with EGFR mutationpositive disease were enrolled. Subsequent retesting with improved sequencing technologies reduced the sample size to 19 patients after an additional 6 patients were excluded (4 were negative for EGFR mutation by amplificationrefractory mutation system polymerase chain reaction sequencing and 2 by next-generation sequencing [NGS] ).
Most patients were female (12/19, 63.2%), the median age was 59 (range, 33-74) years, and all patients had an Eastern Cooperative Oncology Group performance status of 1 and adenocarcinoma histology. After erlotinib treatment, 73.7% of patients (14/19) underwent surgery; the radical resection rate was 68.4% (13/19). Most patients who underwent surgery benefited from neoadjuvant treatment prior to surgical resection and achieved disease control of the target lesion. The objective response rate was 42.1% (8/19) with a 21.1% (4/19) rate of clinical downstaging to T0-3N0M0; 89.5% of patients (17/19) achieved disease control after neoadjuvant therapy (Figure 1 ). In patients who underwent surgery, postoperative pathology showed that seven patients (50.0%) achieved partial response, seven (50.0%) achieved stable disease, and no patients had progressive disease. Among patients who underwent surgery, median disease-free survival calculated from the date of surgery and the date of neoadjuvant therapy was 10.3 months and 12.1 months, respectively. Among all patients who received neoadjuvant therapy, the median PFS and overall survival were 11.2 and 51.6 months, respectively.
To the best of our knowledge, this is the first study to evaluate the role of neoadjuvant EGFR TKI therapy with erlotinib in patients with stage IIIA-N2 EGFR mutationpositive NSCLC. Our findings are encouraging in view of the poor prognosis and limited treatment options available for patients with stage IIIA-N2 NSCLC.
TRIAL INFORMATION

Disease
Lung cancer -NSCLC American Joint Committee on Cancer 7th edition TNM staging system. Diagnoses were histologically demonstrated in every case and confirmed from medical history, chest computed tomography (CT) scan, whole-body positron emission tomography scan (if not possible, abdomen CT scan and bone single-photon emission computed tomography were employed instead), or endobronchial ultrasound transbronchial needle aspiration examination. EGFR mutation testing was done by polymerase chain reaction (PCR)-based direct sequencing at screening and confirmed by amplification-refractory mutation system PCR after enrollment. Prior to study entry, all patients were evaluated by a multidisciplinary team including a medical oncologist, thoracic surgeon, radiologists, and endoscopists.
Study Design and Treatment
This was a prospective, single-arm, phase II clinical trial conducted at Shanghai Chest Hospital in Shanghai, People's Republic of China. Patients were evaluated for progressive disease (PD) after the first treatment cycle (4 weeks). Patients without PD continued with the next treatment cycle, whereas those with PD were managed with standard chemotherapy or chemoradiotherapy. Patients were evaluated by a surgical team to determine whether the tumor was resectable: a second chest CT scan was performed 56 days after erlotinib monotherapy to assess benefits from neoadjuvant therapy, but there were no predefined criteria for resectability. Patients who benefited from erlotinib and were determined to have resectable tumors received surgery followed by a platinum-based chemotherapy regimen. Follow-up evaluations were performed every 3 months for 2 years, or until death. The criteria for nodal downstaging was based on both imaging and postoperative tissue assessment. Tumor response and progression were assessed according to RECIST version 1.0. AEs were graded by the National Cancer Institute Common Terminology Criteria for AEs version 3.0. This study is registered at clinicaltrials.gov (NCT01217619, ESTERN). The planned sample size was 30 patients (to meet the primary endpoint of the radical resection rate).
Quality of Life
Quality of life was evaluated using the Functional Assessment of Cancer Therapy-Lung (FACT-L) Scale (version 4). Assessments included the lung cancer subscale (LCS), physical well-being, social (functional and emotional) well-being, and the Lung Cancer Symptom Scale. Patients completed questionnaires as part of the FACT-L Scale before the study began (day 1), in the middle of the treatment period (day 29), and after treatment with erlotinib (day 56). The trial outcome index was evaluated using physical and functional well-being and LCS subscales.
Gene Mutation Analysis by Next-Generation Sequencing
Eight patients with adequate formalin-fixed, paraffin-embedded (FFPE) tumor sections, both prior to commencing erlotinib treatment and after surgery, underwent NGS analysis. In total, 52 genes were screened on the Illumina NextSeq500 sequencing platform (Illumina, Inc., San Diego, CA); seven mutated genes related to NSCLC therapy, and 45 genes related to other cancer treatments. In all samples, more than 97% of regions were covered by >500× with mean depth over 1,200×. Tissue DNA Extraction DNA was extracted and isolated with the QIAamp DNA FFPE tissue kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. DNA concentration was measured using Qubit dsDNA assay (Thermo Fisher Scientific, Waltham, MA).
Next-Generation Sequencing Library Preparation
Extracted tumor DNA was sheared using the Covaris M220 instrument (Covaris Inc., Woburn, MA), followed by end repair, phosphorylation, and adaptor ligation. Fragments sized 200-400 bp were selected using Agencourt AMPure beads (Beckman Coulter, Brea, CA) followed by hybridization with capture probes baits, hybrid selection with magnetic beads, and PCR amplification. A bioanalyzer high-sensitivity DNA assay was performed to assess the quality and size of the fragments, and indexed samples were sequenced on the NextSeq500 sequencer with pair-end reads.
Sequencing Data Analysis
The sequencing data in the FASTQ format were mapped to reference sequence hg19 (Human Genome version 19) using Burrows-Wheeler Aligner 0.7.10. Local alignment optimization, variant calling, and annotation were performed using Genome Analysis Toolkit 3.2, MuTect, and VarScan, respectively. DNA translocation analysis was performed using both Tophat2 and Factera 1.4.3. Gene-level copy number variation was assessed using a t test statistic after normalizing read depths at each region by total reads number and region size, and correcting GC bias using a LOESS model.
Panel Design
The panel consisted of all exons and critical introns of 56 NSCLC-related genes, spanning 330 kb of human genome. All driver genes and genes associated with targeted therapies (not limited to NSCLC) were included in the panel.
Statistical Methods
Overall response rate was defined as the proportion of patients who achieved a complete response or a partial response. Disease-free survival (DFS) was defined as the time from the date of surgery to tumor recurrence or death from any cause, whichever occurred earlier. PFS was defined as the time from the date of neoadjuvant treatment to the first date of disease progression or death. Overall survival was defined as the time from the date of diagnosis to death from any cause. Efficacy analyses were based on the intention-to-treat (ITT) population, which comprised enrolled patients with confirmed EGFR mutation who received at least one dose of erlotinib. Therefore, response rate, radical resection rate, PFS, and overall survival were analyzed in the ITT population, and DFS was analyzed in patients who underwent surgery. Continuous variables were summarized by mean, standard deviation, median, minimum and maximum, and binary variables were summarized by frequencies and percentages. Student's t test was used to assess change from baseline in quality of life measures, and an analysis of covariance model was used to assess the mean carcinoembryonic antigen differences between patients who did and did not have surgery. All p values were two-sided. Median DFS and median PFS were calculated using the Kaplan-Meier method. SAS 9.2 software (SAS Institute, Cary, NC) was used for statistical analyses.
Investigator's Analysis Active and should be pursued further. 
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ADVERSE EVENTS
See Table 5 . [1] . Patients with stage IIIA-N2 NSCLC whose tumors harbor epidermal growth factor receptor (EGFR) mutations are particularly challenging to treat and have a poor prognosis despite preoperative chemoradiotherapy [2] . Several phase III randomized controlled trials evaluated EGFR tyrosine kinase inhibitor (TKI) therapy in patients with EGFR mutation-positive NSCLC and demonstrated good efficacy and a favorable tolerability profile for EGFR TKI therapy in these patients [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Erlotinib was one of the first TKIs approved for the initial treatment of EGFR mutation-positive NSCLC. In this setting, first-line erlotinib therapy demonstrated superior efficacy over standard chemotherapy, with a more favorable tolerability profile, without the life-threatening toxicities associated with chemotherapies [11, 13, 14]. However, there is no consensus on the optimal treatment strategy for patients with stage IIIA-N2 NSCLC, including those with EGFR mutationpositive disease. The efficacy and tolerability of preoperative EGFR TKI therapy, although promising, requires further research. Therefore, this clinical trial aimed to evaluate whether erlotinib, as a neoadjuvant therapy, improves operability and overall survival (OS) in patients with stage IIIA-N2 EGFR mutation-positive NSCLC.
SERIOUS ADVERSE EVENTS
In total, 155 patients were screened from July 2011 to June 2014; 44 were diagnosed with stage IIIA-N2 NSCLC. Of these 44 patients, 25 patients with EGFR mutation-positive disease were enrolled. Next-generation sequencing (NGS) was repeated during the 3-year recruitment period, during which four patients were found to be negative for EGFR mutation (amplification-refractory mutation system polymerase chain reaction sequencing) and removed from the study. Further NGS analysis reduced our sample to 19 patients with activating EGFR mutations eligible for inclusion in the study (Fig. 1) . Most patients (73.7%; 14/19) underwent surgical resection. Baseline demographic and clinical characteristics are shown in Table 1 .
The tumor was resectable in 14 of 19 patients who received neoadjuvant erlotinib, and the radical resection rate in the overall population was 68.4% (13/19; Table 2 ). Among surgical patients, 35.7% of patients (5/14) had pathological downstaging from N2 to N1/N0, and 50% (7/14) experienced a reduction in tumor size ( Table 3 ). The disease control rate was 89.5% (17/19) after neoadjuvant therapy. A waterfall plot of response to erlotinib neoadjuvant therapy is shown in Figure 2 . There was a greater change from baseline in carcinoembryonic antigen level among patients who underwent surgery versus those who did not (Table 4) . At the end of follow-up, most patients received platinumbased adjuvant chemotherapy (maximum six cycles, mean three cycles); no patients received postoperative radiotherapy.
The Kaplan-Meier curves of disease-free survival, progressionfree survival (PFS), and OS are shown in Figure 3 .
To date, the selection of an optimal treatment regimen for patients with stage IIIA-N2 NSCLC remains controversial, and there is no standard of care for these patients. Our results suggest that neoadjuvant erlotinib improved the likelihood of surgery and was associated with a good resection rate as shown by the high rate of prospective downstaging in patients with stage IIIA-N2 NSCLC. In a study by Noh et al., 52.3% of patients with stage IIIA-N2 NSCLC experienced progressive disease with concurrent chemoradiotherapy, and 7 of 65 patients died from pulmonary radiation therapy-related adverse events (AEs). In this study, the authors reported a resection rate of 86.4% (456/528) among patients judged as medically operable [15] . Dy et al. found that chemotherapy achieved a relatively positive induction response and a radical resection rate of 94% among patients with early-stage IB to IIIA NSCLC who underwent surgery [16] . A small study of patients with resectable IIIA-N2 NSCLC that compared erlotinib versus gemcitabine/carboplatin as neoadjuvant therapy reported response rates of 58.3% versus 25.0% (p = .18), and 54.2% (13/24) patients underwent surgical resection [17] . Compared with these studies, our study demonstrated a strong disease control rate (89.5%) and downstage tumor rate (21.1%). Of note, among the 14 patients who underwent surgery, all but one (93%, 13/14) underwent radical resection. Importantly, patients achieved a median PFS of 11.2 months and median OS of 51.6 months. Taken together, these findings support the use of erlotinib prior to surgery to improve the radical resection rate and long-term survival of patients with IIIA-N2 NSCLC.
Erlotinib as neoadjuvant therapy was well tolerated. AEs occurred in 36.8% (7/19) of patients (Table 5) . No patients died from treatment-related AEs, and only one patient had a grade 4 AE; these findings are comparable with those of a previous study [13] . A comparison of Functional Assessment of Cancer Therapy-Lung and Lung Cancer Symptom Scale scores before and after erlotinib treatment demonstrated improved quality of life after treatment with neoadjuvant erlotinib (Table 6) .
Adequate tissue samples from before neoadjuvant therapy and after surgery were available for eight patients only. Tumor samples for these patients were analyzed for 68 genes by NGS (Tables 7 and 8 and Fig. 4) . Patients who benefited most from neoadjuvant erlotinib therapy (cases 6 and 7), with PFS lasting over 36 months, had no TP53 mutation or very low TP53 abundance. Conversely, the patient with the greatest TP53 abundance (case 8) had limited benefits in PFS (8 months) and OS (16 months). These findings indicate that additional biomarkers may play an important role in predicting response to TKI therapy in the neoadjuvant setting. These results are consistent with, and supportive of, previous findings [18], suggesting that TP53 gene mutation is independently associated with shorter OS in NSCLC.
We acknowledge that the small sample size of our study represents a major limitation. We recruited a specific subset of patients with NSCLC who, in addition to having stage IIIA-N2 disease, were positive for activating EGFR mutations. Our center is one of the largest for clinical lung cancer research in China, yet we encountered challenges with recruiting patients. Nevertheless, we believe that the findings from this study raise important clinical questions and will be helpful for informing larger controlled trials in the future.
In our study, neoadjuvant erlotinib was well tolerated and improved the rate of radical resection in patients with stage IIIA-N2 EGFR mutation-positive NSCLC. NGS analysis allowed us to identify markers that may help predict the clinical course of IIIA-N2 NSCLC. If of predictive value, markers of TP53 abundance could be used to guide preoperative application of TKIs. Given our findings and those of other small studies, we look forward to large-scale randomized controlled trials investigating the role of TKIs in perioperative therapy, combining neoadjuvant and adjuvant treatments to enhance personalized therapy for patients in this precision medicine era.
ACKNOWLEDGMENTS
The authors thank all patients who participated in this trial and their families, as well as the investigators, study coordinators, operation staff, and the whole project team who worked on this study. We also thank Michelle Belanger, M.D., of Edanz Medical Writing for medical writing assistance, funded by Shanghai Roche Pharmaceuticals Ltd. T2aN1M0  IIA  N1  T2a  2  T2bN2M0  T2aN2M0  IIIA  T2a  3  T2bN2M0  T3N0M0  IIIA  N0  4  T2aN2M0  T2aN2M0  IIIA  5  T2aN2M0  T2aN3M0  IIIB   6  T2aN2M0  T2aN2M0  IIIA  7  T2aN2M0  T1aN2M0  IIIA  T1a  8  T2aN2M0  T1aN2M0  IIIA  T1a  9  T2aN2M0  T2aN0M0  IIB  N0  10  T2bN2M0  T2aN2M0  IIIA  T2a  11  T2aN2M0  T2aN2M0  IIIA  12  T2aN2M0  T1bN0M0  IA  N0  T1b  13  T2aN2M0  T3N2M0  IIIA   14  T2aN2M0  T1bN0M0 IA N0 T1b Click here to access other published clinical trials. 
